Search
CEP-1347
go.drugbank.com/drugs/DB05403InvestigationalCEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons
AVAC
go.drugbank.com/drugs/DB05441Experimental[Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate
MBX-2044
go.drugbank.com/drugs/DB05598InvestigationalMBX-2044 was under investigation in clinical trial NCT00422487 (Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes).
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Lintitript
go.drugbank.com/drugs/DB04867ExperimentalLintitript is a new, highly specific and potent CCK-A receptor antagonist.
FG-2216
go.drugbank.com/drugs/DB08687InvestigationalA orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability. [A14422]
XL784
go.drugbank.com/drugs/DB04991InvestigationalXL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation.
PM02734
go.drugbank.com/drugs/DB05158InvestigationalPM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
Actelion-1
go.drugbank.com/drugs/DB05367ExperimentalActelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Categories: Endothelin A Receptor Antagonists